Skip to Main Content

Author Details

Richard G Stock
Icahn School of Medicine at Mount Sinai
1992
216
55
PMIDPaper TitleJournal TitlePublished Year
36179990External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.Int J Radiat Oncol Biol Phys2023
37217695Sexual health and treatment-related sexual dysfunction in sexual and gender minorities with prostate cancer.Nat Rev Urol2023
36889593Outcomes after PD-103 versus I-125 for low dose rate prostate brachytherapy monotherapy: An international, multi-institutional study.Radiother Oncol2023
36588020Clinical and treatment characteristics of secondary bladder malignancies following low dose rate brachytherapy for prostate cancer.Urol Oncol2023
35050303Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.JAMA Oncol2022
35581667Ocular complications with the use of radium-223: a case series.Radiat Oncol2022
35717046Radium-223 for Metastatic Castrate-Resistant Prostate Cancer.Pract Radiat Oncol2022
35902336Comparison of AUA and phoenix definitions of biochemical failure following permanent brachytherapy for prostate cancer.Brachytherapy2022
36289743Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy.Biomedicines2022
35123886Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy.Brachytherapy2022
33075391Salvage low dose rate brachytherapy for prostate cancer recurrence following definitive external beam radiation therapy.Radiother Oncol2021
33840634Live implant dosimetry may be an effective replacement for postimplant computed tomography in localized prostate cancer patients receiving low dose rate brachytherapy.Brachytherapy2021
34902034Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.JAMA Netw Open2021
34509378Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement.Brachytherapy2021
33985797Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.Eur Urol2021
34196715Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.JAMA Netw Open2021
33199175The impact of a rectal hydrogel spacer on dosimetric and toxicity outcomes among patients undergoing combination therapy with external beam radiotherapy and low-dose-rate brachytherapy.Brachytherapy2021
33246636Radiopharmaceuticals for Bone Metastases.Semin Radiat Oncol2021
30992160Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.Eur Urol2020
31959519Prolonged hormonal therapy and external beam radiation independently increase the risk of Persistent Hypogonadism in men treated with prostate brachytherapy.Brachytherapy2020
33083651Survey of Radiation Oncologists to Assess Interest and Potential Use of a Genetic Test Predicting Susceptibility for the Development of Toxicities After Prostate Cancer Radiation Therapy.Adv Radiat Oncol2020
33049542Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade.Cancer Treat Res Commun2020
33132070The American Brachytherapy Society prostate brachytherapy LDR/HDR simulation workshops: Hands-on, step-by-step training in the process of quality assurance.Brachytherapy2020
33178576A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort.Front Oncol2020
32663537Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.Radiother Oncol2020
32763013I-125 or Pd-103 for brachytherapy boost in men with high-risk prostate cancer: A comparison of survival and morbidity outcomes.Brachytherapy2020
32217039Long-term biochemical control and cause-specific survival in men with Gleason grade Group 4 and 5 prostate cancer treated with brachytherapy and external beam irradiation.Brachytherapy2020
32442822A biochemical definition of cure after brachytherapy for prostate cancer.Radiother Oncol2020
32232450Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical Prostatectomy.JAMA Netw Open2020
31095341Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy.J Natl Cancer Inst2020
30635196Long-term oncological and functional outcomes support use of low-dose-rate brachytherapy with or without external beam radiation in young men (⿤60 years) with localized prostate cancer.Brachytherapy2019
29956864Stage T3b prostate cancer diagnosed by seminal vesicle biopsy and treated with neoadjuvant hormone therapy, permanent brachytherapy and external beam radiotherapy.BJU Int2019
30890317Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms.Brachytherapy2019
29319919Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy.BJU Int2018
30061057Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy.Brachytherapy2018
29976500Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.Int J Radiat Oncol Biol Phys2018
29726091Factors influencing long-term urinary symptoms after prostate brachytherapy.BJU Int2018
29509865Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.JAMA2018
29194001Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers.J Oncol Pract2018
29319928Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up.BJU Int2018
27771243American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer.Brachytherapy2017
28274393Low-dose cranial boost in high-risk adult acute lymphoblastic leukemia patients undergoing bone marrow transplant.Pract Radiat Oncol2017
28757403Performance of a palladium-103 line source for prostate brachytherapy implants: A Phase I trial.Brachytherapy2017
27210574Urinary Incontinence Following Prostate Brachytherapy.Urology2016
27743956The impact of timing of salvage hormonal therapy on survival after brachytherapy for prostate cancer.Brachytherapy2016
27515689Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer.EBioMedicine2016
25239396Diagnosis and management of local recurrence after low-dose-rate brachytherapy.Brachytherapy2015
23769266Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer: 20-year experience at Mount Sinai Medical Center.Urol Oncol2014
24787300T2 muscle-invasive bladder cancer.Semin Oncol2014
24603102Prophylactic sildenafil citrate improves select aspects of sexual function in men treated with radiotherapy for prostate cancer.J Urol2014
  • 1 - 50 of 216

Recommended Authors

Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 26
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 17
Jure Murgic
University Hospital Center Sestre Milosrdnice
Career Start Year 2008
Number of shared co-authors 4
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Career Start Year 2008
Number of shared co-authors 8
Bridget F Koontz
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 25
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 6
Mitchell Kamrava
Cedars Sinai Medical Center
Career Start Year 2005
Number of shared co-authors 18
Neil B Desai
University of Texas Southwestern Medical Center
Career Start Year 2004
Number of shared co-authors 26
Andrew K Lee
Texas Center for Proton Therapy
Career Start Year 2001
Number of shared co-authors 3
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 9
Eric Vigneault
Centre Hospitalier Universitaire de Quebec
Career Start Year 1997
Number of shared co-authors 14
Alan Thompson
The Royal Marsden NHS Foundation Trust
Career Start Year 1996
Number of shared co-authors 3
Vincent Khoo
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Career Start Year 1996
Number of shared co-authors 13
Andrew Loblaw
Princess Margaret Hospital, University of Toronto
Career Start Year 1995
Number of shared co-authors 31
Inge M van Oort
Radboud University Medical Center
Career Start Year 1995
Number of shared co-authors 13
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Career Start Year 1993
Number of shared co-authors 18
Alexandre R Zlotta
University Health Network, Princess Margaret Cancer Center, University of Toronto
Career Start Year 1993
Number of shared co-authors 3
William L Barrett
Department of Radiation Oncology University of Cincinnati Cincinnati Ohio USA.
Career Start Year 1992
Number of shared co-authors 1
Neil E Fleshner
University of Toronto
Career Start Year 1989
Number of shared co-authors 21
Mark Frydenberg
Monash University
Career Start Year 1988
Number of shared co-authors 17
Philip Cornford
Liverpool University Hospitals
Career Start Year 1988
Number of shared co-authors 7
Theo M de Reijke
Amsterdam University Medical Centers, University of Amsterdam
Career Start Year 1987
Number of shared co-authors 33
Seth A Rosenthal
Sutter Cancer Centers Radiation Oncology Services
Career Start Year 1987
Number of shared co-authors 40
Freddie C Hamdy
University of Oxford
Career Start Year 1987
Number of shared co-authors 13
Donald B Fuller
Division of Genesis Healthcare Partners Inc., CyberKnife Centers of San Diego Inc.
Career Start Year 1986
Number of shared co-authors 32
Peter Hoskin
Mount Vernon Cancer Centre
Career Start Year 1985
Number of shared co-authors 26
Joseph L Chin
University of Western Ontario
Career Start Year 1982
Number of shared co-authors 4
Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 1976
Number of shared co-authors 56
John Trachtenberg
University of Toronto, University Health Network
Career Start Year 1971
Number of shared co-authors 4
Alan Pollack
University of Miami Miller School of Medicine
Career Start Year 1963
Number of shared co-authors 40

Collaborators

Barry S Rosenstein
Co-authored papers 22
Gregory S Merrick
Urologic Research Institute, Ohio University School of Medicine
Co-authored papers 16
Jay P Ciezki
Cleveland Clinic
Co-authored papers 14
Brian J Davis
Mayo Clinic
Co-authored papers 12
Eric M Horwitz
Fox Chase Cancer Center
Co-authored papers 11
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 10
David Jeffrey Demanes
University of California los angeles
Co-authored papers 9
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Co-authored papers 9
Michael L Steinberg
University of California los angeles
Co-authored papers 9
Amar U Kishan
University of California los angeles
Co-authored papers 9
Patrick A Kupelian
university of california los angeles Medical Center
Co-authored papers 9
David P Atencio
Co-authored papers 9
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 8
Ryan Fiano
Urologic Research Institute, Ohio University School of Medicine
Co-authored papers 8
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 8
Daniel J Krauss
William Beaumont School of Medicine
Co-authored papers 8
Stephen Greco
Johns Hopkins University School of Medicine
Co-authored papers 8
Theodore L DeWeese
Johns Hopkins University School of Medicine
Co-authored papers 8
Danny Y Song
Johns Hopkins University School of Medicine
Co-authored papers 8
Eyad Abu-Isa
Ascension Providence Hospital
Co-authored papers 8
Wolfgang Lilleby
Oslo University Hospital
Co-authored papers 8
Curtiland Deville
Johns Hopkins University
Co-authored papers 8
Trude B Wedde
Oslo University Hospital
Co-authored papers 8
Chandana A Reddy
Cleveland Clinic
Co-authored papers 8
Todd McNutt
Johns Hopkins University School of Medicine
Co-authored papers 7
Brian J Moran
Chicago Prostate Cancer Center
Co-authored papers 7
Ashley E Ross
Northwestern University
Co-authored papers 7
Jeffrey J Tosoian
Vanderbilt University Medical Center
Co-authored papers 7
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 6
Eric A Klein
Cleveland Clinic
Co-authored papers 6
Release 1.2